Longitudinal Anti-HBs Monitoring and Seroprotection Patterns in Rituximab-Treated Patients with Pemphigus Vulgaris: A Retrospective Cohort Study

Nur Ecer, Mehmet Harman · 2026

Read Longitudinal Anti-HBs Monitoring and Seroprotection Patterns in Rituximab-Treated Patients with Pemphigus Vulgaris: A Retrospective Cohort Study by Nur Ecer, Mehmet Harman (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13605555.txt.

Description

Rituximab drains B cells for months, and with them can go the antibodies that guard against hepatitis B. The authors follow 84 patients with pemphigus vulgaris, an autoimmune blistering disease, treated with the drug between 2010 and 2026. All have antibody measurements before and after treatment. The team models the antibody trend over time and asks which patients fall below the standard protection threshold of 10 units per liter.

At the start, the median level is 49.7, yet 40.5 percent already sit below the threshold. Levels dip significantly at months 6, 9, and 18, though the chance of crossing below the threshold does not rise significantly overall. Patients carrying signs of past hepatitis B exposure keep far higher antibody levels. No case of viral reactivation is documented, though viral DNA was not routinely checked. The authors advise serological testing and care in reading serial antibody values in such patients.

Catalog record

CREATORNur Ecer, Mehmet Harman
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE28 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13605555

Browse the full library · About the Tower of Babel